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Transdermal delivery has many advantages over conventional modes of drug ad-
ministration; especially, it avoids hepatic first pass metabolism and improves patient com-
pliance (1). Intensive research has shown that the transdermal route is a potential mode
of delivery of lipophilic drugs in the systemic circulation (2). Nitrendipine (NTP) was
used as the model drug. Nitrendipine is a lipophilic drug used for the management of
mild to moderate essential hypertension. It possesses low oral bioavailability (20 %) due
to hepatic first pass metabolism after oral administration (3). Hence, NTP is an ideal drug
candidate for transdermal drug delivery. In the present study, polymeric films contain-
ing nitrendipine as a model drug and oleic acid as a penetration enhancer (4) were pre-
pared using a novel combination of Eudragit RL 100 and Plasdone S 630 (polyvinyl py-
rollidone vinyl acetate, copovidne)/PVP K 30 (polyvinyl pyrollidone, povidone) for
transdermal application and were evaluated for their physicochemical characteristics as
well as for their in vitro drug release and skin permeation potential.
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The objective of the present work was to develop a suit-
able transdermal drug delivery system for nitrendipine.
Polymeric films of nitrendipine were prepared by the film
casting technique (glass ring) on mercury substrate. They
were evaluated for physicochemical parameters, in vitro
release and ex vivo permeation (heat separated human
epidermis). Release of the drug from the films followed
anomalous transport (0.5 < n < 1).
Polymeric combination containing Eudragit RL 100:PVP
K 30 in a 4:6 ratio showed the best results. Maximum
drug release and skin permeability coefficient in 48 h
were 85.8 % and 0.0142 cm h–1, respectively, in formu-
lation C3 (Eudragit RL 100/Plasdone S 630; 4:6) and
88.0 % and 0.0155 cm h–1, respectively, in formulation,
D3 (Eudragit RL 100/PVP K 30; 4:6). FTIR and TLC stud-
ies indicated no drug and polymer interaction.
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EXPERIMENTAL
Materials
Niterendipine was provided by courtesy of Concept Pharmaceuticals, India. Plas-
done S 630 was donated by Jubliant Organosys, India. Eudragit RL 100 (ERL 100) was re-
ceived as a gift sample from Degussa, India. PVP K 30 was purchased from SD Fine Che-
micals Ltd, India. Dibutyl phthalate (DBP) and oleic acid were purchased from CDH,
India. HPLC grade solvents were purchased from Rankem, India. Other materials used
in the study were of analytical grade. Doubly distilled water was used throughout the
study.
Dose design
The dose to be incorporated in a patch was calculated using the following mathe-
matical equation (1):
drug input (theoretical) = Css ´ ke ´ Vd
giving: 25 mg L–1 ´ 0.057 h–1 ´ 350 L = 498.75 mg h r–1
where Css is concentration at steady state, ke is elimination rate constant and Vd is vol-
ume of distribution.
Dose required for a patch = drug input ´ delivery time
giving: 498.75 mg h–1 ´ 48 h = 24 mg per patch
Development of polymeric films
Polymeric films were prepared by the film casting technique on mercury substrate
(15). Series of C and D formulations were prepared using different ratios of polymers
(Table I), along with 16.66 % (m/m) of nitrendipine, 10 % (m/m) of plasticizer (dibutyl-
phthalate), and 5 % (m/m) of penetration enhancer, oleic acid (based on total polymer
mass) in a mixture of dichloromethane and methanol (50:50, V/V). The resulting solu-
tion was poured into a glass ring of 6.00 cm (internal diameter) and placed into mercury
in a Petri dish. The solvent was allowed to evaporate under ambient conditions (tempera-
ture 32 ± 2 °C, RH 45 ± 5 %) for 24 hours. The dried films of 6.74 cm2 were then cut with
a circular metallic die of 2.93 cm (internal diameter). The films were stored between sheets
of wax paper in a desiccator.
Solubility studies
Solubility studies were carried out by adding an excess amount of drug in 20:80
isopopyl alcohol to phosphate buffer (pH 7.4) and keeping the flasks containing the so-
lutions on a mechanical shaker for 24 h at 25 °C. After 24 h, the solution was transferred
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into test tubes and centrifuged at 2000 rpm for 30 min at room temperature. The test
tubes were placed aside to settle for 30 min. From each test tube, 1 mL of supernatant
was placed into a 100-mL volumetric flask and diluted with blank solution. The mixture
was filtered and absorbance was read at 355 nm with a double beam UV-Vis spectro-
photometer (Systronics PC based double beam spectrophotometer, 2202, Systronics, India).
The amount of drug dissolved was quantified from the standard curve (R2 = 0.9999).
Interaction studies
Interaction studies were conducted on the optimized formulation (D-3) by comparing
at with pure drug, polymers and mixture of drug and polymers on the basis of FTIR
(Jasco 4100, Japan) and TLC (6). IR absorption spectra were taken in the range of 400–4000
cm–1 using the potassium bromide disc method. TLC studies were performed on 0.25-mm
silica gel G plates using ethyl acetate/chloroform (1:9) as developer and iodine vapors
as visualizing agent.
Evaluation of polymeric films
The films were evaluated for physical appearance, moisture content, thickness, flat-
ness, folding endurance, tensile strength (percentage elongation at break), drug content
and mass (6, 7).
In vitro dissolution studies
A modified paddle over disc assembly was used for assessment of drug release from
the films. The film was mounted on the disc and placed at the bottom of the dissolution
vessel. The dissolution medium was 900 mL solution of isopropyl alcohol and isotonic
phosphate buffer of pH 7.4 in the ratio of 20:80. The apparatus was equilibrated to 32 ±
0.5 °C and operated at 50 rpm. The samples (3-mL aliquots) were withdrawn at appro-
priate time intervals up to 48 h, filtered, and analyzed at 355 nm. After each sampling,
an equal volume of drug-free solution of isopropyl alcohol and isotonic phosphate buffer
of pH 7.4, 20:80, was added to the dissolution medium to maintain a constant volume.
Necessary corrections were made to the calculations for the loss of drug due to each
sampling. The experiment was done in triplicate and the mean value was calculated.
Release mechanism
Drug release mechanism was analyzed using the Zero-Order Model, First-Order
Model, Higuchi Model and Korsmeyer-Peppas Model (8).
In vitro permeation studies
The study was approved by the Ethics Committee of ITS-Paramedical (Pharmacy)
College Ghaziabad, India. A fabricated diffusion cell with a diffusional area of 6.74 cm2
was used. Ex vivo skin permeation studies were performed on heat separated human
epidermis. Human cadaver skin (abdominal area) was acquired from the Department of
Anatomy, ITS-Centre for Dental Studies and Research, Muradnagar, India. The subcuta-
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neous fatty tissue was removed with surgical scissors. For permeation experiments,
heat separated human epidermis was prepared (9). The skin was immersed into warm
water at 60 °C for 2 min, the whole epidermal layer was carefully separated from the
dermis using blunt forceps. The obtained epidermis was wrapped in aluminum foil and
stored at –20 °C until use. Before the experiment, the skin was taken out and thawed
until it reached room temperature. It was gently blotted dry with filter paper. The in-
tegrity of the skin was tested microscopically before use in the diffusion cell (10). The
stratum corneum side of the skin was kept in intimate contact with the release surface
of the polymeric film (kept in the donor cell). The receiver phase was a 50-mL mixture
of isopropyl alcohol and IPB of pH 7.4 in the ratio of 20:80 stirred at 500 rpm on a mag-
netic stirrer (11). The contents of the receiver cell were kept at 32 ± 0.5 °C with prewar-
med water flowing through a jacket lined with the receiver cell. The amount of drug
permeated was determined by removing 1-mL samples at appropriate time intervals
up to 48 h followed by UV analysis. The volume was replenished with an equal quan-
tity of prewarmed receiver solution. The amount of drug permeated per square centi-
meter at each time interval was calculated from the calibration curve.
Determination of permeation parameters
Permeation profiles of nitrendipine were constructed by plotting the cumulative
amount of the drug permeated per unit area as a function of time. The graph showed
an initial lag time followed by, the linear phase, which was consistent with the steady-
-state Fickian diffusion. The flux was calculated from the slope. In all experiments, the
same number of data points was taken to calculate the flux (J); the permeability coeffi-
cient (Pc) was calculated by dividing the flux by the initial drug load (C) (12):
Pc = J/C
Statistical analysis
GraphPadIn Stat Version 3.0 Software was used for statistical analysis. The results
were expressed as arithmetic mean ± SD. The statistical analysis was performed using
Student’s t-test and ANOVA. Kolmogorov Smirnov distance (KS) test was performed
to test whether two samples were drawn from identical distributions.
RESULTS AND DISCUSSION
Solubility study
An attempt was made at this point to learn whether the medium 20:80 isopropa-
nol/phosphate buffer pH 7.4 was able to maintain skin conditions in dissolution studies
as well as in permeation studies. The concentration of the drug dissolved (solubility) in
the medium was 2.42 mg mL–1, which is 90.8 times higher than the required solubility
(0.026 mg mL–1) in case of dissolution studies and 5.0 times higher than the required
solubility (0.48 mg mL–1) in case of permeation studies. Results showed that the above
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medium could be chosen as the dissolution and permeation medium because a sufficient
amount of drug, necessary to maintain the sink conditions, dissolves in it. Further, the
above medium does not affect the barrier function of the epidermis as lower alcohol con-
centration does not extract the lipid fraction from the stratum corneum (13, 14).
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Fig. 1. IR spectra of: a) nitrendipine, b) physical mixture of nitrendipine and polymers.
Interaction studies
The Rf values for the pure drug and the mixture were 0.66 and 0.68, respectively.
The IR spectral analysis of nitrendipine alone (Fig. 1a) showed that principal peaks were
observed at wave numbers of 1701.7 (esterified carbonyl group), 1650.4 (N-H bending
vibration for secondary amines), 1531.8 (aryl nitro group), 1096.0 cm–1 (CN vibrations)
and the same peaks at 1701.7, 1651.1, 1530.9, 1099.4 cm–1 were observed in the spectra of
the optimized medicated film (Fig. 1b). Some additional peaks were aso observed in phys-
ical mixtures, which could be due to the presence of polymers. As principal peaks of IR
spectra of pure drug appeared in the IR spectra of medicated film, it can be concluded
that there was no chemical interaction between the drug and the polymers. Further TLC
results support the data obtained from IR spectra that there was no interaction between
the drug and the polymers used in the study.
Evaluation of polymeric films
On the basis of visual characterization, films C1, C2, D1 and D2 were rejected as
they were moderately sticky and wrinkled and it would be difficult to handle such films
and they could not be subjected to any kind of evaluation. The data of the selected films
are presented in Table I and II. The drug content analysis of the prepared films showed
that the process used to prepare the films is capable of giving uniform drug content
(99.5–99.9 % trought both series C and D) and minimum batch variability (Table II). The
results reveal that the films have reasonable flexibility and moderate percentage elonga-
tion. The folding endurance in series C and D is ranges from 92 to 135 % and elongation
at break from 14 to 37 %. The folding endurance decreased with increasing concentra-
tion of PVP/Plasdone S 630. In spite of variations in this physical parameter, all films
were found to be smooth and flexible, which might be attributed to addition of the pla-
sticizer dibutyl phthalate (10 %, m/m, of polymer mass). No constriction was observed in
any of the prepared films, which indicates smooth flat surface of the films.
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Table I. Composition and visual characterization of nitrendipine polymeric films
Code Polymers (ratio) Visual characterization
C3 ERL 100/Plasdone S 630 (4:6) smooth, uniform and flexible
C4 ERL 100/Plasdone S 630 (5:5) smooth, uniform and flexible
C5 ERL 100/Plasdone S 630 (6:4) smooth, uniform and flexible
C6 ERL 100/Plasdone S 630 (7:3) smooth, uniform and flexible
C7 ERL 100/Plasdone S 630 (8:2) smooth, uniform and flexible
D3 ERL 100/PVP K30 (4:6)
slightly sticky, smooth, uniform
and slightly tough
D4 ERL 100/PVP K30 (5:5) smooth, uniform and flexible
D5 ERL 100/PVP K30 (6:4) smooth, uniform and flexible
D6 ERL 100/PVP K30 (7:3) smooth, uniform and flexible
D7 ERL 100/PVP K30 (8:2) smooth, uniform and flexible
In vitro dissolution studies
In this study, the effect of various polymeric combinations on the release behaviour
and kinetics of NTP from transdermal films was evaluated. In order to describe the ki-
netics of drug release from transdermal films, various mathematical models were used
(8). The data is presented in Table III. The release of drug from all the films followed
anomalous transport (0.5 < n < 1); however, films containing higher concentration of co-
povidone/povidone (C3 and D3) showed higher release and exhibited release order
towards the first-order (pseudo first-order) and Fickian diffusion as release mechanism
(n  0.5). Films containing higher content of Eudragit RL 100 showed lesser release and
exhibited release mechanism towards case II transport. The reason for films C3 and D3
to exhibit pseudo Fickian first-order diffusion may be the leaching of PVP/Plasdone S
630 and pore formation. This led to an increase in the external film area exposed to the
solvent, increased internal porosity and decreased tortuosity. With an increase in poros-
ity, the void volume would be expected to be occupied by external solvent diffusing into
the film (15). In case of films C7 and D7, containing a higher content of the rate control-
ling polymer (Eudragit RL 100), lesser release and case II transport release mechanism
might be due to the increase in the time needed to release a given quantity of drug, al-
lowing higher hydration and relaxation of the polymer matrix before release. The release
profiles of the films are shown in Figs. 2a and b. Maximum percentage of drug released
(88.0 %) was found for formulation D3 (PVP/E PO, 6:4) and minimum percentage of
drug released (68.8 %) was observed for film D7 (PVP/E PO, 2:8) in series D formula-
tions. Similar observations were observed in series C films, C3 showed maximum re-
lease of 85.8 %, whereas C7 showed minimum drug release of 60.6 %. Film D3 (con-
taining PVP K 30 polymer) showed higher release than C3 (containing Plasdone S 630).
(Student’s t-test, p = 0.0005, KS = 0.18). Significant differences in drug release were
absowed between films of series C and D (ANOVA, p < 0.05). This might be due to the
389
A. Mittal et al.: Formulation and evaluation of monolithic matrix polymer films for transdermal delivery of nitrendipine, Acta Pharm.
59 (2009) 383–393.




















































































a Mean ± SD, n = 3.
presence of vinyl acetate component in Plasdone S 630 polymer (serias C), which is some-
what more hydrophobic. It appears that water solubility of antinucleating polymers in-
fluences the drug release and permeation of the drug from the matrix type transdermal
film.
In vitro drug permeation studies
Drug permeation profiles from series C and D films were more or less rectilinear
and were indicative of the steady and slow permeation of the drug in vitro (Table IV).
The influence of film composition on permeation parameters is shown in Table IV.
Higher NTP flux was observed with higher concentration of PVP K 30/Plasdone S 630
concentration in films (Table IV). Improvement in skin flux with the increase of PVP K
30/Plasdone S-630 content may be due to its antinucleating effect that converts the crys-
talline drug into an amorphous state, which generally possesses a high energy state with
solubility. Enhancement in drug solubility provides increased thermodynamic activity,
which facilitates skin permeation of the drug (15).
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Fig. 2. In vitro drug release profile of nitrendipine (modified paddle dissolution apparatus in 20:80
isopropyl alcohol/phosphate buffer pH 7.4) from drug matrix patches: a) Eudragit RL/Plasdone S
630 (series C), b) Eudragit RL/PVK K 30 (series D) (mean ± SC, n = 3).
CONCLUSIONS
The nitrendipine polymeric films containing Plasdone S 630 were found to have hi-
gher flexibility compared to those containing PVP K 30. Combination of polymers Eu-
dragit RL 100/PVP K 30 in the ratio of 4:6 showed the best results. In vitro dissolution
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Table IV. In vitro skin permeation parameters of the polymeric films of nitrendipine
Code
In vitro permeation parameter
CADP (48 h) (%)a Flux ´ 104 (mg cm–2 h–1) Pc (mm h–1)
C3 69.2 ± 1.5 508 142
C4 63.9 ± 1.7 471 132
C5 60.1 ± 3.5 442 124
C6 54.9 ± 1.7 405 113
C7 50.1 ± 1.8 371 104
D3 75.4 ± 1.9 554 155
D4 71.5 ± 1.5 523 146
D5 63.3 ± 1.6 467 131
D6 59.4 ± 2.1 437 122
D7 54.1 ± 1.8 399 111
CAPD – Cumulative amount of drug permeated.
Pc – permeability coefficient.
a Mean ± SEM, n = 3.




R2 k0 (% h–1) R2 k1 (% h–1) R2 kH (% h–1/2)
C3 0.978 3.38 0.987 0.0431 0.995 10.33 0.618
C4 0.981 2.91 0.991 0.034 0.994 9.15 0.661
C5 0.979 2.41 0.999 0.029 0.993 8.20 0.800
C6 0.979 2.17 0.999 0.026 0.993 7.47 0.810
C7 0.997 1.85 0.970 0.021 0.931 6.41 0.942
D3 0.979 4.09 0.985 0.052 0.995 11.64 0.510
D4 0.985 3.00 0.989 0.037 0.992 9.44 0.653
D5 0.981 2.50 0.997 0.031 0.992 8.45 0.784
D6 0.982 1.98 0.994 0.031 0.988 7.06 0.888
D7 0.993 1.31 0.964 0.015 0.929 5.11 0.952
k0 – zero-order rate constant, k1 – first-order rate constant, kH – Higuchi rate constant, n – Korsmeyer-Peppas
release exponent
studies revealed that the release of the drug from the films followed anomalous trans-
port (0.5 < n < 1); however, films containing higher levels of PVP/Plasdone S 630 sho-
wed the release mechanism towards Fickian first-order diffusion whereas those contain-
ing higher concentration of Eudragit 100 showed pseudo case II transport mechanism.
In vitro permeation indicated zero-order kinetics in all the films prepared. The release of
the drug was sustained and it extended over a period of 48 h in all developed films. The
IR and TLC studies revealed that there was no interaction between the drug and the
polymers used for making matrices. The above data thus support the assimption that
these films might be suitable for transdermal application.
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S A @ E T A K
Formulacija i evaluacija monolitnih matriksnih polimernih
filmova za transdermalnu isporuku nitrendipina
ASHU MITTAL, UDAI VIR SINGH SARA i ASGAR ALI
Cilj rada bio je razvoj transdermalnog sustava nitrendipina. Polimerni filmovi ni-
trendipina pripravljeni su metodom lijevanja (stakleni prsten) na podlozi od `ive. Ispi-
tivani su fizi~kokemijski parametri, in vitro osloba|anje i ex vivo permeacija (toplinom
odvojena humana epiderma). Osloba|anje lijeka iz filmova slijedilo je anomalni trans-
port (0,5 < n < 1). Najbolji rezultati postignuti su kombinacijom polimera Eudragit RL
100 i PVP K 30 u omjeru 4:6. Maksimalno osloba|anje ljekovite tvari i najbolji koeficijent
permeacije kroz ko`u tijekom 48 h bio je 85,8 %, odnosno 0,0142 cm h–1 za formulaciju
C3 (Eudragit RL 100 : Plasdone S 630; 4:6) i 88,0 %, odnosno 0,0155 cm h–1 za formulaciju
D3 (Eudragit RL 100 : PVP K 30; 4:6). FTIR i TLC ukazuju na to da nema interakcije iz-
me|u ljekovite tvari i polimera.
Klju~ne rije~i: polimerni film, nitrendipin, transdermalni sustav za isporuku lijekova, Eudragit RL
100, Plasdone S 630, PVP K 30
ITS-Paramedical (Pharmacy) College, Ghaziabad, India
D. J. College of Pharmacy, Ghaziabad, India
Deparment of Pharmaceutics, Faculty of Pharmacy, Hamdard University, New Delhi, India
393
A. Mittal et al.: Formulation and evaluation of monolithic matrix polymer films for transdermal delivery of nitrendipine, Acta Pharm.
59 (2009) 383–393.
